Plus Therapeutics shares are trading lower after the company announced a licensing agreement with Biocept.
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics has entered into a licensing agreement with Biocept, causing its shares to trade lower.
September 08, 2023 | 7:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Plus Therapeutics' stock is trading lower after the company announced a licensing agreement with Biocept.
The announcement of the licensing agreement with Biocept has led to a decrease in Plus Therapeutics' stock price. This could be due to investors' concerns about the financial implications of the agreement or uncertainty about its potential benefits.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100